Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

- 1 min read

Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments

New York, NY, December 15, 2022 (PRNewswire) -- Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments for depression and other mental health disorders, today announced the closing of a $39 million Series B round of financing. The round was led by Prime Movers Lab with additional investment from Alumni Ventures, Palo Santo, Negev Capital, Route 66, JLS Fund, Satori Capital and Gron Ventures. The additional capital will be used, in part, to further advance Gilgamesh's 2 lead programs, GM-1020 and GM-2505 through Phase 1/1b safety and efficacy studies.

Read full article here.

Recent Posts

See All

Boundless Bio Secures $100M Series C Funding to Advance ecDNA-Directed Therapies for Oncogene Cancer

San Diego, CA, May 16, 2023 (Business Wire) -- Boundless Bio, a pioneering precision oncology company, has successfully raised $100 million in a Series C financing round led by Leaps by Bayer and RA

Vitor Rocha Takes the Helm as President of Cepheid, Driving Global Healthcare Innovations

Sunnyvale, CA, May 23, 2023 (Cepheid) -- Cepheid, a renowned molecular diagnostics company, has appointed Vitor Rocha as its new President. With over 20 years of experience in the medical devices in

ReNAgade Therapeutics Secures $300 Million Series A Funding to Revolutionize RNA Medicine

Cambridge, MA, May 23, 2023 (Business Wire) -- ReNAgade Therapeutics, a cutting-edge company focused on harnessing the full potential of RNA medicines for disease correction, has successfully raised

Boundless Bio Secures $100M Series C Funding to Advance ecDNA-Directed Therapies for Oncogene Cancer

Vitor Rocha Takes the Helm as President of Cepheid, Driving Global Healthcare Innovations

ReNAgade Therapeutics Secures $300 Million Series A Funding to Revolutionize RNA Medicine

Dave Rosa named President of Intuitive

ElevateBio Secures $401M Series D Financing, Spearheading Advancements in Cell and Gene Therapies

Syneos Health to be Acquired for Approximately $7.1 Billion by a Private Investment Consortium

DermTech names Bret Christensen, former chief commercial officer of Insulet, as its new President

Healthy.io raises $50 million in series D funding to accelerate adoption of at-home kidney test

Ron Renaud Appointed to Lead Cerevel Therapeutics as President and Chief Executive Officer

Baxter to sell biopharma unit for $4.25 billion

Executive Spotlights

Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments

Recent Posts

Life Science Headlines